Allogeneic haemopoietic stem cell transplantation (SCT) is the only curative option for severe bone marrow (BM) failure in patients with Fanconi anaemia (FA). We have developed a non total body irradiation (TBI) conditioning protocol consisting of fludarabine (120-150 mg/m 2 ), low dose of cyclophosphamide (40 mg/kg) and antilymphocyte globulin (45 mg/kg). Graft-versus-host disease (GVHD) prophylaxis was with cyclosporin alone for sibling allografts but also included Campath-1 H (days 1-5 post SCT) for the unrelated allografts. We have performed two sibling and two unrelated BM transplants with a follow-up of 11-51 months. All patients experienced minimal toxicity and were discharged from hospital 28-32 days post SCT. Neutrophil and platelet engraftment occurred from days 11 to 19 and 15 to 34, respectively. All patients achieved stable full donor haemopoiesis with normalisation of the peripheral blood count despite one of them having myelodysplasia (MDS) with 8% blasts prior to the SCT. The only site of acute GVHD was in the skin (grade I-II) and only one patient progressed to limited chronic GVHD. This protocol is associated with reduced toxicity and prompt engraftment in FA patients with AA and/or MDS undergoing SCT using sibling or unrelated donors.
Summary:
Allogeneic haemopoietic stem cell transplantation (SCT) is the only curative option for severe bone marrow (BM) failure in patients with Fanconi anaemia (FA). We have developed a non total body irradiation (TBI) conditioning protocol consisting of fludarabine (120-150 mg/m 2 ), low dose of cyclophosphamide (40 mg/kg) and antilymphocyte globulin (45 mg/kg). Graft-versus-host disease (GVHD) prophylaxis was with cyclosporin alone for sibling allografts but also included Campath-1 H (days 1-5 post SCT) for the unrelated allografts. We have performed two sibling and two unrelated BM transplants with a follow-up of 11-51 months. All patients experienced minimal toxicity and were discharged from hospital 28-32 days post SCT. Neutrophil and platelet engraftment occurred from days 11 to 19 and 15 to 34, respectively. All patients achieved stable full donor haemopoiesis with normalisation of the peripheral blood count despite one of them having myelodysplasia (MDS) with 8% blasts prior to the SCT. The only site of acute GVHD was in the skin (grade I-II) and only one patient progressed to limited chronic GVHD. This protocol is associated with reduced toxicity and prompt engraftment in FA patients with AA and/or MDS undergoing SCT using sibling or unrelated donors. Bone Marrow Transplantation (2003) 32, 653-656. doi:10.1038/sj.bmt.1704219 Keywords: Fanconi anaemia; fludarabine; sibling donors; stem cell transplantation; volunteer unrelated donors Fanconi anaemia (FA) is an autosomal recessive disease characterised by a variable number of somatic abnormalities including those of the skeleton (including absent or abnormal thumbs and radii), skin, kidneys, gastrointestinal tract, heart and brain. The majority of patients will develop progressive bone marrow failure and have a high predisposition to malignancy, particularly to the development of acute myeloid leukaemia. 1 Not only is the clinical presentation highly variable, but the disease also displays substantial genetic heterogeneity. The genes mutated in the different FA subtypes (FA-A to FA-G) have all been identified, and recent studies suggest that their products (which include BRCA2) cooperate in a common DNA damage-response pathway, the FA/BRCA pathway. 2, 3 Such observations now provide a basis for the spontaneous chromosomal instability and hypersensitivity of FA cells to DNA crosslinking agents such as mitomycin C (MMC) and diepoxybutane (DEB). 4, 5 The development of bone marrow failure, and eventual myelodysplastic or leukaemic transformation in many patients, is the main cause of premature mortality. Although many different therapies, including gene therapy, have been tried, the only curative modality for the bone marrow failure is haemopoietic stem cell transplantion (SCT). Conventional doses of alkylating agents used in the conditioning regimen, particularly the use of cyclophosphamide at 200 mg/kg, and irradiation produce high toxicity 6, 7 and an increased rate of malignancies (42% by 20 years) 8, 9 when compared with patients with idiopathic aplastic anaemia (IAA). The high occurrence of severe graft-versus-host disease (GVHD) is a significant cause of transplant-related mortality and appears in multivariate analysis as one of the most important risk factors for the development of secondary cancers. 9 In order to reduce acute toxicity, the use of cyclophosphamide has been reduced to as low as 20 mg/kg, in combination with 4-6 Gy thoracoabdominal irradiation. For many years this had become the standard protocol in use for transplanting FA patients using HLA-compatible sibling donors. 9, 10 However, long-term follow-up has demonstrated that protocols containing irradiation are associated with a higher risk of secondary malignancies. 10 For patients in myelodysplastic transformation or with an unrelated donor there is yet no international consensus on a protocol (s).
In the light of these issues, we have developed a low toxicity SCT protocol based on the use of fludarabine, lowdose cyclophosphamide and antilymphocyte globulin, which excludes irradiation. This protocol produces sufficient immunosuppression for both related and unrelated transplants, yet has an adequate antileukaemia effect in those with myelodysplastic transformation.
Patients and SCT conditioning
Four patients have undergone stem cell transplantation following this new protocol, two (P1-SIB1 and P2-SIB2) with HLA-compatible sibling donors and two (P3-VUD1 and P4-VUD2) with volunteer unrelated donors.
P1-SIB1 was a 17-year-old female at the time of transplantation, having been diagnosed at 4 years of age with associated oculocutaneous albinism, congenital dislocation of both hips, short stature, developmental delay, a dysmorphic kidney and limb abnormalities. She was diagnosed to have FA on the basis of a positive DEB stress test but no molecular studies were performed. She had received several RBC transfusions for hip surgery prior to the transplant and this had resulted in the generation of anti-M, anti-S, anti-Fy(a) and HLA allo-antibodies. At the time of the SCT she had a hypocellular bone marrow (BM) with trilineage myelodysplasia and 8% myeloblasts. Cytogenetic analysis demonstrated that 18% of metaphases had at least one additional chromosome (18% 47-49, XX,
. A report of this transplant and early follow-up has been published previously.
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P2-SIB2 was diagnosed to have FA at age 5 years and was subsequently shown to belong to the FA complementation group A. He had short stature, several cafe au lait spots, thumb abnormalities, characteristic 'Fanconi facies' and developmental delay. He developed progressive bone marrow failure for which he was initially treated with oxymetholone. However, he had a poor response to the oxymetholone and went on to have an SCT at age 7 years.
P3-VUD1 first presented with features of aplastic anaemia (AA) at age 9 years. He was initially diagnosed to have idiopathic AA and was treated with two courses of antilymphocyte globulin. This failed to improve his blood count and during this time he received regular RBC and platelet transfusions. He was re-evaluated at age 11 years and a diagnosis of FA was made, initially on a positive DEB stress test and subsequently substantiated at the genetic level by the identification of mutations in the FANCA (Fanconi anaemia complementation group A) gene. He was then treated with oxymetholone to which he showed a good haematological response but gradually he became refractory to this and again required blood products. At age 15 years he was recommended for unrelated SCT. By this stage he had significant iron overload (Ferritin was 2700 mg/l), abnormal liver function tests and multiple HLA alloantibodies.
P4-VUD2 had to be delivered at 36 weeks by caesarean section because of fetal distress. Her birth weight was 1.53 kg and she required surgery for duodenal atresia at birth. Subsequently, many abnormalities were identified including growth failure (height and weight below 3rd centile for age), 'Fanconi facies', abnormal thumbs, ventricular septal defect and a small left kidney. A diagnosis of FA was made on positive DEB and MMC stress tests and subsequently she was found to be FAcomplementation group A. At age 3 years she developed severe thrombocytopenia and this gradually progressed to pancytopenia. She had only a partial response to oxymetholone and was aged 4 years at the time of SCT.
The conditioning regimen for patients (P1-SIB1 and P2-SIB2) transplanted using HLA-compatible sibling donors consisted of fludarabine 120 mg/m 2 (30 mg/m 2 /day from day À9 to day À6), cyclophosphamide 40 mg/kg (10 mg/ kg/day from day À6 to day -3) and horse antilymphocyte globulin 45 mg/kg (15 mg/kg/day from day À4 to day À2). GVHD prophylaxis was with cyclosporin from day À1 to 6 months post SCT. For patients (P3-VUD1 and P4-VUD2) transplanted with unrelated donors the protocol was the same but with the following modifications. Firstly, the fludarabine was increased to 150 mg/m 2 (30 mg/m 2 /day from day -10 to day -6). Secondly, in addition to CSA, for GVHD prophylaxis, patients received Campath-1 H (anti-CD52) 2.5 mg/kg (0.5 mg/kg/day from day þ 1 to day þ 5).
The BM nucleated cell doses were 4.9 Â 10 8 , 7.5 Â 10 8 , 4.1 Â 10 8 , and 8.8 Â 10 8 cells/kg for P1-SIB1, P1-SIB2, P3-VUD1, P4-VUD2, respectively. The grafts were not manipulated (no T-cell depletion performed). The CMV serological status was negative for all the individuals except for the donor of P1-SIB2, who was CMV-Ab positive.
The donor/host origin of haemopoiesis was assessed by Southern blot analysis of DNA extracted from whole blood or marrow using Msp1 restriction digestion and the YNH24 probe or Pst1 digestion and the M27b probe. This was performed initially at 1 month post transplantation and then 3 monthly thereafter.
Results
Engraftment was rapid in all cases. Both patients who received sibling allografts achieved a neutrophil count40.5x10 9 /l on day 11 post transplantation. This was achieved at days 19 and 15 in P3-VUD1 and P4-VUD2, respectively. Unsupported platelet counts4 50 Â 10 9 /l were achieved on days 22 and 15 in P1-SIB1 and P2-SIB2, respectively; days 34 and 13 for P3-VUD1 and P4-VUD2. A lymphocyte count consistently above 1.0 Â 10 9 /l was achieved on days 38 and 70 in P1-SIB1 and P2-SIB2, respectively; days 48 and 60 for P3-VUD1 and P4-VUD2 (Table 1) . Stable full-donor haemopoiesis was observed in all patients by Southern blot analysis from the first point of testing at 1 month post SCT ( Figure 1 ) and was sustained in all patients.
Transplant-related toxicity was minimal. Only P1-SIB1 (10 days) and P3-VUD1 (5 days) received total parenteral nutrition and requirements for intravenous opioids were low (1-10 days). The in-patient stay was short and patients (P1-SIB1, P2-SIB2, P3-VUD1, P4-VUD2) were discharged from hospital on day þ 29, þ 28, þ 32 and þ 34 post SCT, respectively. Only P4-VUD2 required readmission, precipitated by a central line related sepsis and thrombus that resolved completely following removal of the catheter and treatment with anticoagulants and intravenous antibiotics.
The only site of acute GVHD was in the skin, grade I in P1-SIB1 and P3-VUD1 and grade II in P2-SIB2 and P2-VUD2. This progressed to limited chronic GVHD in P3-VUD1 treated with low-dose prednisolone therapy.
None of the patients suffered infection with CMV. The only viral infection of note has been a herpes zoster in P1-SIB1 at 2 years post SCT. In January 2003, all four patients Non-TBI transplantation protocol for Fanconi anaemia (P1-SIB1, P2-SIB2, P3-VUD1 and P4-VUD2) were alive with a follow-up of 51, 30, 23 and 11 months, respectively. All of them had 100% Karnofsky scores and normal peripheral blood counts.
Discussion
Allogeneic stem cell transplantation is the only treatment that can restore normal haemopoiesis in FA, thereby preventing the main cause of mortality in this disease. Due to the hypersensitivity of FA cells to alkylating agents and irradiation, standard conditioning protocols for IAA have resulted in substantially poorer results due to the high incidence of transplant-related mortality, particularly organ damage and GVHD. 8 While in HLA-matched allografts, adequate engraftment with a significant reduction in toxicity has been achieved by reducing the dose of alkylating agents and irradiation, there are still significant concerns about the high incidence of epidermoid carcinoma after long-term follow up of these patients. 9 In addition, the adequacy of the protocols for patients with myelodysplastic transformation is uncertain. 12 Furthermore, the availability of HLA-matched related donors is restricted and the use of unrelated donors has a significantly worse outcome. 13, 14 Guardiola et al reported the outcome of 69 allogeneic stem cell transplants for FA using HLA-matched unrelated donors on behalf of the European Group for Blood and Marrow Transplantation. The 3-year probability of survival was only 33%. The probability of grade III-IV acute GVHD was 34% and the use of T-cell depletion did not improve the outcome, despite the dramatic reduction in GVHD, because of the increased risk of graft failure. 15 Fludarabine-containing nonmyeloablative stem cell transplant protocols in non-FA patients have been shown to allow the engraftment of HLA-matched stem cells with a lower transplant-related toxicity than previous regimens and optimisation of the immune effect of the graft to eradicate the original disease. 16, 17 There are some reports in the literature of the use of this modality in patients with FA. 11, [18] [19] [20] [21] However, as far as we are aware, there are no published reports of successful unrelated transplants performed without the use of irradiation. Also, there appears to be no single protocol suitable for both related and unrelated allografts and applicable to the different stages (AA/MDS) of this heterogeneous disease.
To address these questions we designed a protocol that allows prompt and stable engraftment. This was observed even in the two patients who received unrelated allografts despite the use of in vivo T-cell depletion. Although this manoeuvre has significantly reduced the incidence and severity of GVHD, in previous studies it has been associated with a substantial degree of graft failure that has offset any benefit in the outcome of transplantation. 15 Yet, with this protocol it seems possible to achieve engraftment without the risk of severe GVHD. Sustained engraftment has been observed even in the presence of significant HLA allo-antibodies in two (P1-SIB1 and P3-VUD1) out of the four patients, a well-recognised risk factor for graft failure. 22 Moreover, two prominent features in our patients, extensive malformations and the use of androgens before transplant, have previously been associated with a worse outcome. 15 Furthermore, one of the patients (P3-VUD1) had significant iron overload and abnormalities of liver function at the time of SCT. With a follow-up ranging from 11 to 51 months, we have not seen any clinical problems related to the immune reconstitution of these patients. The low toxicity and early discharge make the regimen particularly suitable for the paediatric age group.
In conclusion, this protocol is associated with reduced toxicity and prompt stable engraftment in FA patients with AA and/or MDS using both sibling and unrelated donors. As it avoids irradiation, it might be associated with a reduced risk of secondary malignancies in the long term. Further information on more patients and longer follow-up is necessary to determine if this indeed will be the case.
